Osimertinib

SEP 9, 2026 · OBSERVATIONAL STUDY

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

ClinicalTrials.gov

This is a registry record for an active observational study with no results posted; it describes planned enrollment and methods only, without outcome data.

SEP 9, 2026 · PHASE 3 TRIAL

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

ClinicalTrials.gov

This is an active clinical trial registry record with no posted results; the study design and planned endpoints are documented but outcome data are not yet reported.

SEP 8, 2026 · PHASE 2 TRIAL

A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

ClinicalTrials.gov

Phase 2 interventional trial with planned safety and efficacy endpoints in EGFR-mutant NSCLC; no results reported in this registry record.

AUG 20, 2026 · PHASE 2 TRIAL

Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

ClinicalTrials.gov

This is a Phase 2 trial registration with no posted results; it describes a planned neoadjuvant study in a specific population but cannot yet demonstrate efficacy or safety.

AUG 20, 2026 · PHASE 3 TRIAL

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

ClinicalTrials.gov

This is a Phase 3 RCT registry record with no posted results; the study is active but not recruiting, and outcomes remain unreported in this source.

AUG 19, 2026 · PHASE 2 TRIAL

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

ClinicalTrials.gov

This is an active, ongoing Phase 2 trial registration with no results posted; the design and planned endpoints are reported but outcome data are not yet available.

AUG 18, 2026 · PHASE 1/2 TRIAL

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

ClinicalTrials.gov

This is an ongoing Phase 1/2 trial registration with no results reported; it describes planned safety and tolerability endpoints in a combination drug study for advanced solid tumors.

AUG 13, 2026 · PHASE 1 TRIAL

Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer

ClinicalTrials.gov

Phase 1b dose-escalation trial with no results reported; this is a registry record describing a planned study design, not outcome data.